Across TCGA pan-cancer cohorts, HSPB11 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of HSPB11’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HSPB11 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HSPB11 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.
CCRCC, HNSC, and PDAC are the cancer types where HSPB11 tumor–normal differential expression is most reproducible.